touchFEATURE The role of fibroblast growth factor receptor (FGFR) alterations in advanced urothelial carcinoma
Watch to learn more about FGFR alterations and how a consensus on molecular classification impacts our understanding of muscle-invasive bladder cancer.1,2
The details matter in the treatment of advanced urothelial cancers
This short video summarises the role of molecular profiling in advanced urothelial carcinomas.1,2
1/3 Next ChapterAn introduction to the fibroblast growth factor receptor (FGFR)
This video infographic introduces the involvement of FGFR alterations in tumorigenesis, and their prevalence in various cancer types including urothelial carcinoma.3-6
2/3 Next ChapterCould a molecular understanding of disease change our approach to advanced urothelial carcinoma?
Dr Ignacio Durán, Medical Oncologist at Hospital Universitario Marqués de Valdecilla, Spain, discusses a consensus molecular classification for muscle-invasive bladder cancer and how this may lead to more targeted approaches in the treatment of advanced urothelial carcinoma.2
3/3 Leave FeedbackOverview & Learning Objectives
Overview
Fibroblast growth factor receptor (FGFR) alterations are present in a wide variety of tumour types, including urothelial carcinoma.1-3 Alterations in the FGR/FGFR pathway can cause aberrant signalling that is implicated in multiple tumorigenic processes.4-6 A consensus molecular classification for muscle-invasive bladder cancer defines a subtype expressing a high percentage of FGFR alterations.2 This consensus may open the door to more targeted approaches in the treatment of advanced urothelial carcinoma.2
For more information, please visit FGFR alterations in oncology.
Â
Learning Objectives
After watching this activity, participants should be better able to:
- Understand the FGFR pathway and its potential involvement in urothelial carcinoma5
- Recognise that FGFR alterations are common in certain types of urothelial carcinoma3
- Discuss a consensus molecular classification for muscle-invasive bladder cancer and its potential impact on clinical practice2
References
- Inamura K. Bladder Cancer: New Insights into Its Molecular Pathology. Cancers. 2018;10(4):100.
- Kamoun A, de Reyniès A, Allory Y, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020;77(4):420-33.
- Helsten T, Elkin S, Arthur E, et al. he FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2016;22(1):259-267.
- Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014; 34(2):280-300.
- Presta M, Chiodelli P, Giacomini A, et al. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017;179:171-187.
- Ahmad I, Iwata T, Leung HY, et al. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta. 2012;1823(4):850-860.